Significant preclinical efficacy in various cancers, including lymphoma, SCLC, and other solid tumors. Although resistance due to Mcl-1 expression and thrombocytopenia posed challenges, combination strategies and dose management provided effective solutions. This evidence concerns the gene MCL1 and lymphoma.